{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-009805","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.897337+00:00","generated_at":"2026-05-16T01:41:25.352069+00:00","sec_items":["5.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Vanda Pharmaceuticals sets 2025 bonuses, 2026 salaries, and grants RSUs/PSUs to executives","bullets":["CEO Polymeropoulos gets $834,326 2025 bonus; 2026 base $994,625, target bonus 80%.","Other NEOs 2025 bonuses $272k-$282k; 2026 base $576,735-$596,990, target 45%.","RSUs: 525,000 to CEO, 125,000 to each of four other NEOs; vest in 4 equal annual installments.","PSUs: target 175,000 (CEO), 40,000 (others); payout 0%-150% based on relative TSR vs Nasdaq Biotech Index over 3 years.","Compensation Committee used Willis Towers Watson peer analysis in determining compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-009805","json":"https://secwatch.observer/filing/0001628280-26-009805.json","markdown":"https://secwatch.observer/filing/0001628280-26-009805.md","text":"https://secwatch.observer/filing/0001628280-26-009805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026009805/0001628280-26-009805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026009805/vnda-20260218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:41:25.352069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}